Praxis Precision Medicines Inc. (PRAX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
Praxis Precision Medicines Q2 Earnings Call Highlights
Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, or DEEs, as both new drug applications remain under FDA review.
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor
Praxis Precision Medicines, Inc. is valued as a pure-play on ulixacaltamide's commercial launch in essential tremor, with pipeline optionality limited. I maintain a cautious Hold rating, as PRAX trades above my fair value estimate of $223.73 versus a current share price of $265. Key risks include real-world persistence, payer step edits, and competition from cheap off-label generics, which could materially limit ulixacaltamide's addressable market and duration.
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines NASDAQ: PRAX said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026 results and pipeline updates on the company's earnings call.
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential
Praxis Precision Medicines, Inc. remains a Strong Buy, driven by two NDA submissions and pipeline expansion opportunities targeting essential tremor and developmental and epileptic encephalopathies. The company's relutrigine achieved a 46% placebo-adjusted reduction in motor seizure frequency for SCN2A/SCN8A DEE and is under FDA priority review with a PDUFA date of September 27, 2026. Pipeline expansion includes relutrigine's potential sNDA for broad DEE and elsunersen for early-onset SCN2A DEE, with key data readouts expected in 2026–2027.
Praxis Precision Medicines, Inc. $PRAX Shares Sold by B Group Inc.
B Group Inc. trimmed its holdings in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) by 10.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,500 shares of the company's stock after selling 3,500 shares during the quarter. Praxis Precision Medicines
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
Deerfield Management Company increased its PRAX stake by 62,500 shares in the fourth quarter; the estimated transaction value was $11.64 million based on quarterly average prices. Meanwhile, the quarter-end value of the PRAX position rose by $221.69 million, reflecting both the share addition and price appreciation during the period.
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
Driehaus Capital Management added 432,510 shares of PRAX in the fourth quarter; the estimated value of the transaction was $80.54 million. Meanwhile, the quarter-end position value rose by $248.48 million, reflecting both share purchases and stock price movement.
